Skip to main content
Log in

Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment

  • Review
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Dabigatran etexilate is an oral, reversible direct thrombin inhibitor and has been recently approved for the prevention of stroke in patients with non-valvular atrial fibrillation. This review describes the incidence and management of stroke and related complications in patients on dabigatran etexilate. Dabigatran is a rapidly acting, and highly selective and reversible inhibitor of thrombin. It also has a potent inhibitory effect on thrombin-induced platelet aggregation, making it effective in preventing both venous and arterial thrombosis. The activated partial thromboplastin time, ecarin clotting time and thrombin time are sensitive tests to evaluate the anticoagulant effects of dabigatran. The rate of ischemic stroke is significantly lower in patients on 150 mg of dabigatran etexilate as compared to 110-mg dose or warfarin (9.2, 13.4, 12 per 1,000 patients, respectively). As there is no standard coagulation test for dabigatran; treatment of acute stroke in such patients is debatable. Careful clinical consideration is required before administering thrombolytic therapy in this patient population. The rate of hemorrhagic stroke was 1.2 and 1.0 per 1,000 patients treated on 110 and 150 mg of dabigatran, respectively. As there is no specific antidote, the only treatment option is discontinuation of the drug and supportive management. Other treatment options, though not clinically proven, include specific reversal agents, which can be individualized according to the severity of the hemorrhage. Dabigatran should be discontinued before invasive procedures depending on the degree of renal impairment and risk of bleeding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–40.

    Article  PubMed  Google Scholar 

  2. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118–23.

    Article  PubMed  Google Scholar 

  3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American College of Cardiology/American heart association task force on practice guidelines and the European Society of cardiology committee for practice guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48(4):854–906.

    Article  PubMed  Google Scholar 

  4. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175–9.

    Article  PubMed  CAS  Google Scholar 

  5. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84(2):527–539.

    Google Scholar 

  6. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323(22):1505–1511.

    Google Scholar 

  7. Boysen G, Godtfredsen J, Andersen ED, Andersen B. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18(2):349–55.

    Article  Google Scholar 

  8. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med. 1992;327(20):1406–12.

    Article  PubMed  CAS  Google Scholar 

  9. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) study group. Lancet 1993; 342(8882): 1255–1262.

  10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.

    PubMed  Google Scholar 

  11. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501.

    PubMed  CAS  Google Scholar 

  12. Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother. 2010;11(8):1403–11.

    Article  PubMed  CAS  Google Scholar 

  13. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.

    Article  PubMed  CAS  Google Scholar 

  14. Eriksson BI, Friedman RJ. Friedman, dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009;15(Suppl 1):25S–31S.

    Article  PubMed  CAS  Google Scholar 

  15. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9.

    Article  PubMed  Google Scholar 

  16. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–56.

    Article  PubMed  CAS  Google Scholar 

  17. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85.

    Article  PubMed  CAS  Google Scholar 

  18. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103–11.

    Article  PubMed  CAS  Google Scholar 

  19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  PubMed  CAS  Google Scholar 

  20. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45(9):1757–66.

    Article  PubMed  CAS  Google Scholar 

  21. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009; 15:9S–16S.

    Google Scholar 

  22. Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs. 2004;64(6):577–95.

    Article  PubMed  CAS  Google Scholar 

  23. Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7(7):557–8.

    Article  PubMed  CAS  Google Scholar 

  24. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP) assessment report for Pradaxa. 2008 12/28/2009]; Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf.

  25. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98(1):155–62.

    PubMed  CAS  Google Scholar 

  26. Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008;68(12):1699–709.

    Article  PubMed  CAS  Google Scholar 

  27. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303.

    Article  PubMed  CAS  Google Scholar 

  28. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59.

    Article  PubMed  CAS  Google Scholar 

  29. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127.

    Google Scholar 

  30. Ulehlova J, Slavik L, Krcova V, et al. Laboratory monitoring of dabigatran during orthopedic surgery (abstract PP-WE-142). J Thromb Haemost. 2009;7(Suppl 2):674.

    Google Scholar 

  31. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003;33:173–83.

    Article  PubMed  CAS  Google Scholar 

  32. Advisory Committee Briefing Document. 2010 1/13/2011]; Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf.

  33. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010;30(5):533–534.

    Google Scholar 

  34. Interventional Management of Stroke (IMS) III Trial (IMS III); Available from: http://clinicaltrials.gov/ct2/show/NCT00359424.

  35. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010;8(4):790–8.

    Article  PubMed  CAS  Google Scholar 

  36. Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006;63(8):1057–62.

    Article  PubMed  Google Scholar 

  37. Dempfle CE, Hennerici MG. Dabigatran and stroke thrombolysis. Cerebrovasc Dis. 2010;30(2):203–5.

    Article  PubMed  Google Scholar 

  38. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–63.

    Article  PubMed  CAS  Google Scholar 

  39. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–7.

    Article  PubMed  CAS  Google Scholar 

  40. Sartori MT, Imbergamo S, Zanon E, et al. Effect of recombinant activated Factor VII in critical bleeding: clinical experience of a single center. Clin Appl Thromb Hemost. 2009;15:628–35.

    Article  PubMed  CAS  Google Scholar 

  41. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–43.

    Article  PubMed  CAS  Google Scholar 

  42. Fernlöf G, Sjöström BM, Lindell KM, et al. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. Blood Coagul Fibrinolysis. 2009;20:667–74.

    Article  PubMed  Google Scholar 

  43. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49:259–68.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

 Dr. Qureshi has received funding from National Institutes of Health RO-1-NS44976-01A2 (medication provided by ESP Pharma) and 1U01NS062091-01A2, American Heart Association Established Investigator Award 0840053 N, and Minnesota Medical Foundation, Minneapolis, MN.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adnan I. Qureshi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watanabe, M., Siddiqui, F.M. & Qureshi, A.I. Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment. Neurocrit Care 16, 203–209 (2012). https://doi.org/10.1007/s12028-011-9591-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-011-9591-y

Keywords

Navigation